Highlights
- Mayne Pharma starts Tuesday still digesting a quarter in which underlying earnings fell sharply. As Mayne Pharma continues operating within the All Ordinaries, growing attention is also being directed towards ASX Technical Analysis as companies across the sector navigate changing market conditions.
- The stock is stuck in the lower a large share of its October range after a sharp late-week reversal.
- A contested board vote at the annual meeting later this month adds another catalyst for the chart.
Mayne Pharma
(ASX:MYX)
Mayne Pharma Group Ltd (ASX:MYX)
…
